PMID- 33552465
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2042-0188 (Print)
IS  - 2042-0196 (Electronic)
IS  - 2042-0188 (Linking)
VI  - 12
DP  - 2021
TI  - The potential role of incretin-based therapies for polycystic ovary syndrome: a 
      narrative review of the current evidence.
PG  - 2042018821989238
LID - 10.1177/2042018821989238 [doi]
LID - 2042018821989238
AB  - INTRODUCTION: Polycystic ovary syndrome (PCOS) is a common endocrine disorder 
      that affects women of reproductive age. Metabolic consequences associated with 
      PCOS include, but are not limited to, insulin resistance (IR), type 2 diabetes 
      mellitus (T2DM) and cardiovascular disease (CVD). This narrative review aims to 
      provide a comprehensive overview of the potential therapeutic roles of the 
      incretin-based therapies in the management of PCOS. METHODS: We performed a 
      systematic search of databases including PubMed, MEDLINE and EMBASE up to 1 
      October 2020. We developed a search string of medical subject headings (MeSH) 
      including the terms PCOS, incretin mimetics, glucagon-like peptide-1 (GLP-1), 
      glucagon-like peptide-1 receptor antagonists (GLP-1 RAs), liraglutide, exenatide, 
      semaglutide, dipeptidyl peptidase-4 (DPP-4) inhibitors, combined with IR, 
      testosterone and sex hormone-binding globulin (SHBG). RESULTS: We identified 854 
      relevant articles and, after the initial screening, eight interventional animal 
      studies, one observational animal study, 14 interventional human studies, two 
      case-control studies and one systematic review were included. These studies 
      showed the potential significant roles of GLP-1 RAs and DPP-4 inhibitors in the 
      management of PCOS, with significant improvements in the metabolic parameters, 
      including substantial weight reduction and improved insulin sensitivity. These 
      agents also improved the hormonal parameters through decreased free androgen and 
      increased SHBG. Moreover, they improved menstrual regularity, increased fertility 
      with enhanced ovulation and pregnancy in obese women with PCOS. CONCLUSION: GLP-1 
      RAs and DPP-4 inhibitors have a promising therapeutic role in PCOS; however, 
      larger clinical trials are needed to establish the role of incretin-based 
      therapies in the management of PCOS.
CI  - (c) The Author(s), 2021.
FAU - Abdalla, Mohammed Altigani
AU  - Abdalla MA
AUID- ORCID: 0000-0002-6016-3157
AD  - Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical 
      School, University of Hull, Hull, UK.
FAU - Deshmukh, Harshal
AU  - Deshmukh H
AD  - Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical 
      School, University of Hull, Hull, UK.
FAU - Atkin, Stephen
AU  - Atkin S
AD  - School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, 
      Kingdom of Bahrain.
FAU - Sathyapalan, Thozhukat
AU  - Sathyapalan T
AD  - Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical 
      School, University of Hull, Hull, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210127
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC7844452
OTO - NOTNLM
OT  - DPP-4
OT  - GLP-1 RAs
OT  - PCOS
OT  - dipeptidyl peptidase-4 inhibitors
OT  - exenatide
OT  - glucagon-like peptide-1
OT  - infertility
OT  - insulin resistance
OT  - liraglutide
OT  - obesity
OT  - polycystic ovary syndrome
OT  - sitagliptin
OT  - vildagliptin
COIS- Conflict of interest: The authors declare that there is no conflict of interest.
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
PMCR- 2021/01/27
CRDT- 2021/02/08 05:37
PHST- 2020/10/05 00:00 [received]
PHST- 2021/01/03 00:00 [accepted]
PHST- 2021/02/08 05:37 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
PHST- 2021/01/27 00:00 [pmc-release]
AID - 10.1177_2042018821989238 [pii]
AID - 10.1177/2042018821989238 [doi]
PST - epublish
SO  - Ther Adv Endocrinol Metab. 2021 Jan 27;12:2042018821989238. doi: 
      10.1177/2042018821989238. eCollection 2021.